Sentences with phrase «treatment for lung cancer patients»

«Process to help personalize treatment for lung cancer patients developed.»

«We urgently need new treatments for lung cancer patients, and this research suggests we can boost the effectiveness of an existing drug, rather than switch to another new expensive treatment.

Not exact matches

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

«One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed.

Since the Lung Cancer Mutation Consortium trial began in 2009, many patients are now tested for mutated or altered genes before treatment.

«There has been a tremendous effort over the past several years to block EGFR as a treatment for lung cancer, but this therapy only works in a small subset of patients.

«Blocking both of these proteins could be a treatment that is beneficial for the majority of lung cancer patients,» said Dr. Habib, Associate Professor of Neurology and Neurotherapeutics with UT Southwestern's Peter O'Donnell Jr..

«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.

«FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness: Insights derived from FDG PET could improve treatment selection for patients with advanced non-small cell lung cancer.»

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

Few existing treatments offer durable survival benefits for patients whose NSCLC has spread past the lungs, due in part to the aggressive nature of lung cancer and its propensity to progress, even following treatment.

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.

This will establish sequential crizotinib followed by a second generation ALK inhibitor as the standard treatment for patients with metastatic ALK positive lung cancer.»

«This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient,» says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana - Farber.

«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»

«Rapid advancements in genetic testing offer new treatment options for patients with advanced lung cancer.

«But even more importantly, for patients, our ability to identify the similarities could allow treatments for other cancers like lung to be used for certain breast cancers down the road.»

«For about 80 percent of our patients with lung cancer, we don't have tests like [the one for] ALK to tell us what treatments will work best,» Shaw saFor about 80 percent of our patients with lung cancer, we don't have tests like [the one for] ALK to tell us what treatments will work best,» Shaw safor] ALK to tell us what treatments will work best,» Shaw says.

This poor performance is sadly typical for lung cancer treatments: Most are effective for between 3 and 15 percent of patients.

«We wanted to look at the patients» tumor and immune system prior to treatment and examine it again after treatment for changes,» said Patrick Forde, first author and co-principle investigator of the trial and a lung cancer oncologist in the Bloomberg ~ Kimmel Institute of Cancer Immunothcancer oncologist in the Bloomberg ~ Kimmel Institute of Cancer ImmunothCancer Immunotherapy.

The drugs are already approved for treatment of patients with advanced breast cancer as well as ovarian, pancreatic and certain lung cancers.

«Programs that provide treatment for lung cancer also must measure their performance actively and carefully in order to improve the quality of care and improve patients» chances of survival.»

«It takes too long for patients who have suspected lung cancer to get final treatment, and too many patients skip vital steps needed to decide the best possible treatment,» said Dr. Osarogiagbon.

«Lung cancer care is complicated, and all key specialists must be actively engaged early on with each patient to determine the best sequence of tests and treatment for each individual,» said Dr. Osarogiagbon.

Using only patients who had surgery for suspected lung cancer, the researchers examined how long it took to begin care and what steps were taken to determine appropriate treatment.

Patients undergoing surgery for lung cancer may wait too long to receive treatment, and too many patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to an article in the August 2015 issue of The Annals of Thoracic Patients undergoing surgery for lung cancer may wait too long to receive treatment, and too many patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to an article in the August 2015 issue of The Annals of Thoracic patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to an article in the August 2015 issue of The Annals of Thoracic Surgery.

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses osimertinib (Tagrisso) for the treatment of patients with non — small cell lung cCancer Center, discusses osimertinib (Tagrisso) for the treatment of patients with non — small cell lung cancercancer.

The FDA granted approval to durvalumab (IMFINZI ®, AstraZeneca), a checkpoint immunotherapy that targets the PD - 1 / PD - L1 pathway, for patients with unresectable, stage III non-small cell lung cancer (NSCLC) that hasn't progressed after prior chemo - radiation treatment.

The FDA approved Opdivo ® (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) after prior therapy.

On October 2, 2015, the FDA approved the immunotherapy drug pembrolizumab (Keytruda ®), made by Merck, as second - line treatment for patients with lung cancer, the leading cause of cancer - related death in the U.S. and the world.

Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide.

April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.

Of particular interest was urethral sparing during permanent seed implants for prostate brachytherapy and measurement of breathing pattern changes for patients undergoing external beam treatment for lung cancer.

One treatment for patients with early stage non-small cell lung cancer is a form of radiation called stereotactic body radiation therapy (SBRT).

City of Hope patients have access to a wide variety of clinical trials looking into early - detection for lung cancer, the newest chemotherapy treatments, targeted therapies and surgical and radiation approaches — all with the goal of helping extend life.

For patients with early - stage non-small cell lung cancer (NSCLC), the only recommended treatment option is surgery.

Personalised medicine is becoming relevant in the treatment of lung cancer [42, 43] and may have relevance for other lung diseases, like pulmonary fibrosis, asthma and pulmonary hypertension, but disease - related basic research aimed at searching for biomarkers is needed to achieve personalised and patient - specific treatments for lung diseases.

A new treatment, developed by Kimmel Cancer Center researchers, delivers radioactive «seeds» into the airways, extending life for inoperable lung cancer patCancer Center researchers, delivers radioactive «seeds» into the airways, extending life for inoperable lung cancer patcancer patients.

The international early Phase II trial led by a team based at the Oxford Cancer Research Centre will trial the experimental drug called LY2181308 with advanced non-small cell lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this Cancer Research Centre will trial the experimental drug called LY2181308 with advanced non-small cell lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this group.

We are excited to evaluate our technology in combination with pembrolizumab as a potential treatment for lung cancer, and about the promise it may hold for patients,» said Turnstone CEO Sammy Farah, PhD.

The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two - third trial, showed that patients who were taking two different doses of Keytruda (FDA - approved two mg / kg dose and treatment dose of 10 mg / kg given every three weeks) had longer survival compared to those who took docetaxel, the drug widely used for non-small cell lung cancer (NSCLC).

This drug will be used for patients with metastatic or advanced lung cancer who did not respond to previous treatments.

Immunotherapy is a great advance in cancer treatment but up to a quarter of lung cancer patients are not eligible for this therapy.

Inform and educate clinicians as to updates and revisions of their Molecular testing Guideline for the Selection of Lung cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors.

The company's initial goal is to identify and deploy therapeutic neo-antigens from individual patients» tumors to develop novel treatments for lung cancer.

If clinical trials of anti-PD-1 continue to show promising results, cancer patients may soon have access to another powerful immunotherapy for the treatment of numerous cancers, including melanoma, non-small cell lung cancer, and other solid tumors.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Linase Inhibitors 2018